Molecular Docking Assessment of Efficacy of Different Clinically Used Arsenic Chelator Drugs

<table class="table-group" width="800px"><tr class="fig-image" id="a"><td><img alt="396768.fig.002a" src="https://static.hindawi.com/articles/jcm/volume-2013/396768/figures/396768.fig.002a.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(a) </b>Actin</td></tr></table></td></tr><tr class="fig-image" id="b"><td><img alt="396768.fig.002b" src="https://static.hindawi.com/articles/jcm/volume-2013/396768/figures/396768.fig.002b.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(b) </b>ER-Alpha</td></tr></table></td></tr></table>

<table>SAN binding with actin (a) and ER-alpha (b).</table>

Journal of Computational Medicine

fig2

Figure 2

Figure 2: Molecular Docking Assessment of Efficacy of Different Clinically Used Arsenic Chelator Drugs 